Search

Your search keyword '"Evangelista G"' showing total 84 results
Start Over Author "Evangelista G" Search Limiters Full Text
84 results on '"Evangelista G"'

3. Physically Inspired Models for the Synthesis of Stiff Strings with Dispersive Waveguides

Author

Testa I, Evangelista G, and Cavaliere S

Subjects
physical models, dispersive waveguides, frequency warping, Telecommunication, TK5101-6720, Electronics, TK7800-8360
Abstract

We review the derivation and design of digital waveguides from physical models of stiff systems, useful for the synthesis of sounds from strings, rods, and similar objects. A transform method approach is proposed to solve the classic fourth-order equations of stiff systems in order to reduce it to two second-order equations. By introducing scattering boundary matrices, the eigenfrequencies are determined and their dependency is discussed for the clamped, hinged, and intermediate cases. On the basis of the frequency-domain physical model, the numerical discretization is carried out, showing how the insertion of an all-pass delay line generalizes the Karplus-Strong algorithm for the synthesis of ideally flexible vibrating strings. Knowing the physical parameters, the synthesis can proceed using the generalized structure. Another point of view is offered by Laguerre expansions and frequency warping, which are introduced in order to show that a stiff system can be treated as a nonstiff one, provided that the solutions are warped. A method to compute the all-pass chain coefficients and the optimum warping curves from sound samples is discussed. Once the optimum warping characteristic is found, the length of the dispersive delay line to be employed in the simulation is simply determined from the requirement of matching the desired fundamental frequency. The regularization of the dispersion curves by means of optimum unwarping is experimentally evaluated.

Published
2004
Full Text
View/download PDF

4. Sensitivity of Italian dams' flood mitigation capacity to the combined effect of morphological and climatological factors

Author

Evangelista, G., Ganora, D., Mazzoglio, P., Pianigiani, F., and Claps, P.

Abstract

The management of reservoirs during flood events has been widely investigated to support real-time gates operation. However, there is still an insufficient elaboration of the assessment of average peak flow mitigation of dams to be used, for instance, in flood frequency analyses.Here the “natural” flood attenuation potential of 265 large reservoirs all over Italy is devised, in terms of the development of a Mitigation Efficiency Ranking (MER) based on just a few basin and dam essential factors. Simplified, yet rigorous and homogeneous assessment of MER can be used to prioritise the implementation of Dam Emergency Plans in Italy and to support similar initiatives worldwide.To maintain homogeneity in such a wide area, standardized hydrograph shapes are used and index-flood from the rational method is adopted as the incoming peak value, enhancing the results of a recent analysis of all Italian rainfall extremes. The attenuation index is computed by solving the differential equation of lakes. Twenty-four different design floods were derived adopting only two hydrograph shapes and minimal parameter options, i.e., the basin runoff coefficient, the time of concentration and the parameters of the Intensity-Duration-Frequency (IDF) curve. The MER results for the 265 dammed watersheds in all the tested configurations demonstrate to be strongly sensitive to the assumptions on the time of concentration and to some rainfall features, while, for instance, the hydrograph shape seems to exert much less influence on the ranking outcome. This analysis will be part of the research framework of the RETURN Extended Partnership Project.&nbsp, The 28th IUGG General Assembly (IUGG2023) (Berlin 2023)

Published
2023
Full Text
View/download PDF

5. Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, RealWorld Study

Author

Lattanzi, S., Canafoglia, L., Canevini, M. P., Casciato, S., Cerulli Irelli, E., Chiesa, V., Dainese, F., De Maria, G., Didato, G., Di Gennaro, G., Falcicchio, G., Fanella, M., Ferlazzo, E., Gangitano, M., La Neve, A., Mecarelli, O., Montalenti, E., Morano, A., Piazza, F., Pizzanelli, C., Pulitano, P., Ranzato, F., Rosati, E., Tassi, L., Di Bonaventura, C., Alicino, A., Ascoli, M., Assenza, G., Avorio, F., Badioni, V., Banfi, P., Bartolini, E., Basili, L. M., Belcastro, V., Beretta, S., Berto, I., Biggi, M., Billo, G., Boero, G., Bonanni, P., Bongorno, J., Brigo, F., Caggia, E., Cagnetti, C., Calvello, C., Cesnik, E., Chianale, G., Ciampanelli, D., Ciuffini, R., Cocito, D., Colella, D., Contento, M., Costa, C., Cumbo, E., D'Aniello, A., Deleo, F., Difrancesco, J. C., Di Giacomo, R., Di Liberto, A., Domina, E., Dono, F., Durante, V., Elia, M., Estraneo, A., Evangelista, G., Faedda, M. T., Failli, Y., Fallica, E., Fattouch, J., Ferrari, A., Ferreri, F., Fisco, G., Fonti, D., Fortunato, F., Foschi, N., Francavilla, T., Galli, R., Gazzina, S., Giallonardo, A. T., Giorgi, F. S., Giuliano, L., Habetswallner, F., Izzi, F., Kassabian, B., Labate, A., Luisi, C., Magliani, M., Maira, G., Mari, L., Marino, D., Mascia, A., Mazzeo, A., Meletti, S., Milano, C., Nilo, A., Orlando, B., Paladin, F., Pascarella, M. G., Pastori, C., Pauletto, G., Peretti, A., Perri, G., Pezzella, M., Piccioli, M., Pignatta, P., Pilolli, N., Pisani, F., Pisani, L. R., Placidi, F., Pollicino, P., Porcella, V., Pradella, S., Puligheddu, M., Quadri, S., Quarato, P. P., Quintas, R., Renna, R., Rizzo, G. R., Rum, A., Salamone, E. M., Savastano, E., Sessa, M., Stokelj, D., Tartara, E., Tombini, M., Tumminelli, G., Vaudano, A. E., Ventura, M., Vigano, I., Viglietta, E., Vignoli, A., Villani, F., Zambrelli, E., Zummo, L., Lattanzi, Simona, Canafoglia, Laura, Canevini, Maria Paola, Casciato, Sara, Cerulli Irelli, Emanuele, Chiesa, Valentina, Dainese, Filippo, De Maria, Giovanni, Didato, Giuseppe, Di Gennaro, Giancarlo, Falcicchio, Giovanni, Fanella, Martina, Ferlazzo, Edoardo, Gangitano, Massimo, La Neve, Angela, Mecarelli, Oriano, Montalenti, Elisa, Morano, Alessandra, Piazza, Federico, Pizzanelli, Chiara, Pulitano, Patrizia, Ranzato, Federica, Rosati, Eleonora, Tassi, Laura, and Di Bonaventura, Carlo

Subjects
Antiseizure medication, Focal seizures, Brivaracetam, Epilepsy, Neurology, Settore MED/26 - Neurologia, Neurology (clinical), Settore MED/26, Settore MED/39 - Neuropsichiatria Infantile
Abstract

Introduction: In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Most real-world research on BRV has focused on refractory epilepsy. The aim of this analysis was to assess the 12-month effectiveness and tolerability of adjunctive BRV when used as early or late adjunctive treatment in patients included in the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). Methods: BRIVAFIRST was a 12-month retrospective, multicenter study including adult patients prescribed adjunctive BRV. Effectiveness outcomes included the rates of sustained seizure response, sustained seizure freedom, and treatment discontinuation. Safety and tolerability outcomes included the rate of treatment discontinuation due to adverse events (AEs) and the incidence of AEs. Data were compared for patients treated with add-on BRV after 1-2 (early add-on) and ≥ 3 (late add-on) prior antiseizure medications. Results: A total of 1029 patients with focal epilepsy were included in the study, of whom 176 (17.1%) received BRV as early add-on treatment. The median daily dose of BRV at 12months was 125 (100-200) mg in the early add-on group and 200 (100-200) in the late add-on group (p

Published
2022

7. Radiosensitizing effect of curcumin-loaded lipid nanoparticles in breast cancer cells

Author

Minafra, L, Porcino, N, Bravatà, V, Gaglio, D, Bonanomi, M, Amore, E, Cammarata, F, Russo, G, Militello, C, Savoca, G, Baglio, M, Abbate, B, Iacoviello, G, Evangelista, G, Gilardi, M, Bondì, M, Forte, G, Minafra L, Porcino N, Bravatà V, Gaglio D, Bonanomi M, Amore E, Cammarata FP, Russo G, Militello C, Savoca G, Baglio M, Abbate B, Iacoviello G, Evangelista G, Gilardi MC, Bondì ML, Forte GI., Minafra, L, Porcino, N, Bravatà, V, Gaglio, D, Bonanomi, M, Amore, E, Cammarata, F, Russo, G, Militello, C, Savoca, G, Baglio, M, Abbate, B, Iacoviello, G, Evangelista, G, Gilardi, M, Bondì, M, Forte, G, Minafra L, Porcino N, Bravatà V, Gaglio D, Bonanomi M, Amore E, Cammarata FP, Russo G, Militello C, Savoca G, Baglio M, Abbate B, Iacoviello G, Evangelista G, Gilardi MC, Bondì ML, and Forte GI.

Abstract

In breast cancer (BC) care, radiotherapy is considered an efficient treatment, prescribed both for controlling localized tumors or as a therapeutic option in case of inoperable, incompletely resected or recurrent tumors. However, approximately 90% of BC-related deaths are due to the metastatic tumor progression. Then, it is strongly desirable to improve tumor radiosensitivity using molecules with synergistic action. The main aim of this study is to develop curcumin-loaded solid nanoparticles (Cur-SLN) in order to increase curcumin bioavailability and to evaluate their radiosensitizing ability in comparison to free curcumin (free-Cur), by using an in vitro approach on BC cell lines. In addition, transcriptomic and metabolomic profiles, induced by Cur-SLN treatments, highlighted networks involved in this radiosensitization ability. The non tumorigenic MCF10A and the tumorigenic MCF7 and MDA-MB-231 BC cell lines were used. Curcumin-loaded solid nanoparticles were prepared using ethanolic precipitation and the loading capacity was evaluated by UV spectrophotometer analysis. Cell survival after treatments was evaluated by clonogenic assay. Dose-response curves were generated testing three concentrations of free-Cur and Cur-SLN in combination with increasing doses of IR (2-9 Gy). IC50 value and Dose Modifying Factor (DMF) was measured to quantify the sensitivity to curcumin and to combined treatments. A multi-"omic" approach was used to explain the Cur-SLN radiosensitizer effect by microarray and metobolomic analysis. We have shown the efficacy of the Cur-SLN formulation as radiosensitizer on three BC cell lines. The DMFs values, calculated at the isoeffect of SF = 50%, showed that the Luminal A MCF7 resulted sensitive to the combined treatments using increasing concentration of vehicled curcumin Cur-SLN (DMF: 1,78 with 10 µM Cur-SLN.) Instead, triple negative MDA-MB-231 cells were more sensitive to free-Cur, although these cells also receive a radiosensitization effect b

Published
2019

8. Correction to: Adjunctive Brivaracetam in Focal Epilepsy: Real‑World Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST) (CNS Drugs, (2021), 10.1007/s40263-021-00856-3)

Author

Lattanzi, S., Canafoglia, L., Canevini, M. P., Casciato, S., Chiesa, V., Dainese, F., De Maria, G., Didato, G., Falcicchio, G., Fanella, M., Ferlazzo, E., Fisco, G., Gangitano, M., Giallonardo, A. T., Giorgi, F. S., La Neve, A., Mecarelli, O., Montalenti, E., Piazza, F., Pulitano, P., Quarato, P. P., Ranzato, F., Rosati, E., Tassi, L., Di Bonaventura, C., Alicino, A., Ascoli, M., Assenza, G., Avorio, F., Badioni, V., Banfi, P., Bartolini, E., Basili, L. M., Belcastro, V., Beretta, S., Berto, I., Biggi, M., Billo, G., Boero, G., Bonanni, P., Bongorno, J., Brigo, F., Caggia, E., Cagnetti, C., Calvello, C., Irelli, E. C., Cesnik, E., Chianale, G., Ciampanelli, D., Ciuffini, R., Cocito, D., Colella, D., Contento, M., Costa, C., Cumbo, E., D'Aniello, A., Deleo, F., Difrancesco, J. C., Gennaro, G., Di Giacomo, R., Di Liberto, A., Domina, E., Donato, F., Dono, F., Durante, V., Elia, M., Estraneo, A., Evangelista, G., Faedda, M. T., Failli, Y., Fallica, E., Fattouch, J., Ferrari, A., Ferreri, F., Fonti, D., Fortunato, F., Foschi, N., Francavilla, T., Galli, R., Gazzina, S., Giuliano, L., Habetswallner, F., Izzi, F., Kassabian, B., Labate, A., Luisi, C., Magliani, M., Maira, G., Mari, L., Marino, D., Mascia, A., Mazzeo, A., Meletti, S., Morano, A., Nilo, A., Orlando, B., Paladin, F., Pascarella, M. G., Pastori, C., Pauletto, G., Peretti, A., Perri, G., Pezzella, M., Piccioli, M., Pignatta, P., Pilolli, N., Pisani, F., Pisani, L. R., Placidi, F., Pollicino, P., Porcella, V., Pradella, S., Puligheddu, M., Quadri, S., Quintas, R., Renna, R., Rossi, J., Rum, A., Salamone, E. M., Savastano, E., Sessa, M., Stokelj, D., Tartara, E., Tombini, M., Tumminelli, G., Ventura, M., Vigano, I., Viglietta, E., Vignoli, A., Villani, F., Zambrelli, E., and Zummo, L.

Published
2021

9. Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)

Author

Lattanzi, S., Canafoglia, L., Canevini, M. P., Casciato, S., Chiesa, V., Dainese, F., De Maria, G., Didato, G., Falcicchio, G., Fanella, M., Ferlazzo, E., Fisco, G., Gangitano, M., Giallonardo, A. T., Giorgi, F. S., La Neve, A., Mecarelli, O., Montalenti, E., Piazza, F., Pulitano, P., Quarato, P. P., Ranzato, F., Rosati, E., Tassi, L., Di Bonaventura, C., Alicino, A., Ascoli, M., Assenza, G., Avorio, F., Badioni, V., Banfi, P., Bartolini, E., Basili, L. M., Belcastro, V., Beretta, S., Berto, I., Biggi, M., Billo, G., Boero, G., Bonanni, P., Bongorno, J., Brigo, F., Caggia, E., Cagnetti, C., Calvello, C., Irelli, E. C., Cesnik, E., Chianale, G., Ciampanelli, D., Ciuffini, R., Cocito, D., Colella, D., Contento, M., Costa, C., Cumbo, E., D'Aniello, A., Deleo, F., Difrancesco, J. C., Di Gennaro, G., Di Giacomo, R., Di Liberto, A., Domina, E., Donato, F., Dono, F., Durante, V., Elia, M., Estraneo, A., Evangelista, G., Faedda, M. T., Failli, Y., Fallica, E., Fattouch, J., Ferrari, A., Ferreri, F., Fonti, D., Fortunato, F., Foschi, N., Francavilla, T., Galli, R., Gazzina, S., Giuliano, L., Habetswallner, F., Izzi, F., Kassabian, B., Labate, A., Luisi, C., Magliani, M., Maira, G., Mari, L., Marino, D., Mascia, A., Mazzeo, A., Meletti, S., Morano, A., Nilo, A., Orlando, B., Paladin, F., Pascarella, M. G., Pastori, C., Pauletto, G., Peretti, A., Perri, G., Pezzella, M., Piccioli, M., Pignatta, P., Pilolli, N., Pisani, F., Pisani, L. R., Placidi, F., Pollicino, P., Porcella, V., Pradella, S., Puligheddu, M., Quadri, S., Quintas, R., Renna, R., Rossi, J., Rum, A., Salamone, E. M., Savastano, E., Sessa, M., Stokelj, D., Tartara, E., Tombini, M., Tumminelli, G., Ventura, M., Vigano, I., Viglietta, E., Vignoli, A., Villani, F., Zambrelli, E., Zummo, L., Lattanzi S., Canafoglia L., Canevini M.P., Casciato S., Chiesa V., Dainese F., De Maria G., Didato G., Falcicchio G., Fanella M., Ferlazzo E., Fisco G., Gangitano M., Giallonardo A.T., Giorgi F.S., La Neve A., Mecarelli O., Montalenti E., Piazza F., Pulitano P., Quarato P.P., Ranzato F., Rosati E., Tassi L., and Di Bonaventura C.

Subjects
medicine.medical_specialty, business.industry, Context (language use), Brivaracetam, medicine.disease, Discontinuation, law.invention, Psychiatry and Mental health, Epilepsy, Randomized controlled trial, Tolerability, focal epilepsy, add-on therapy, seizure, law, Concomitant, Internal medicine, Medicine, Pharmacology (medical), Neurology (clinical), Levetiracetam, Original Research Article, business, medicine.drug
Abstract

Background: In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Studies performed in a naturalistic setting are a useful complement to characterize the drug profile. Objective: This multicentre study assessed the effectiveness and tolerability of adjunctive BRV in a large population of patients with focal epilepsy in the context of real-world clinical practice. Methods: The BRIVAFIRST (BRIVAracetam add-on First Italian netwoRk STudy) was a retrospective, multicentre study including adult patients prescribed adjunctive BRV. Patients with focal epilepsy and 12-month follow-up were considered. Main outcomes included the rates of seizure‐freedom, seizure response (≥50% reduction in baseline seizure frequency), and treatment discontinuation. The incidence of adverse events (AEs) was also considered. Analyses by levetiracetam (LEV) status and concomitant use of strong enzyme-inducing antiseizure medications (EiASMs) and sodium channel blockers (SCBs) were performed. Results: A total of 1029 patients with a median age of 45years (33–56) was included. At 12 months, 169 (16.4%) patients were seizure-free and 383 (37.2%) were seizure responders. The rate of seizure freedom was 22.3% in LEV-naive patients, 7.1% in patients with prior LEV use and discontinuation due to insufficient efficacy, and 31.2% in patients with prior LEV use and discontinuation due to AEs (p&nbsp

Published
2021

17. Data Analysis methods for non-Gaussian, non-stationary and non-linear features and their application to Virgo

Author

Acernese, F., Amico, P., Arnaud, N., Babusci, D., Ballardin, G., Barillé, R., Barone, F., Barsuglia, M., Beauville, F., Bellachia, F., Bizouard, M. A., Boccara, C., Boget, D., Bondu, F, Bourgoin, C., Bozzi, A., Braccini, S., Bradaschia, C., Brillet, A., Brisson, V., Brocco, L., Buskulic, D., Cachenaut, J., Calamai, G., Calloni, E., Campagna, E., Casciano, C., Cattuto, C., Cavalier, F., Cavaliere, S., Cavalieri, R., Cella, G., Chassande Mottin, E., Chollet, F., Cleva, F., Cokelaer, T., Conforto, G., Cortese, S., Coulon, J. P., Cuoco, E., Dattilo, V., Davíd, P. Y., Davier, M., De Rosa, M., De Rosa, R., Di Fiore, L., Di Virgilio, A., Dujardin, B., Dominici, P., Eleuteri, A., Enard, D., Evangelista, G., Ferrante, I., Fidecaro, F., Fiori, I., Flaminio, R., Forest, D., Fournier, J. D., Fournier, L., Frasca, Sergio, Frasconi, F., Gammaitoni, L., Ganau, P., Gennai, A., Gennaro, G., Giacobone, L., Giazotto, A., Giordano, G., Girard, C., Gougoulat, G., Guidi, G. M., Heitmann, H., Hello, P., Hermel, R., Heusse, P., Holloway, L., Honglie, F., Iannarelli, M., Journet, L., Krecklbergh, S., Lagrange, B., La Penna, P., Leliboux, M., Lieunard, B., Lomtadze, T., Loriette, V., Losurdo, G., Loupias, M., Mackowski, J. M., Majorana, Ettore, Man, C. N., Marchesoni, F., Marion, F., Martelli, F., Masserot, A., Massonnet, L., Mataguez, S., Menzinger, F., Mazzoni, M., Michel, C., Milano, L., Montorio, J. L., Moreau, F., Moreau, J., Morgado, N., Mornet, F., Mours, B., Mugnier, P., Nenci, F., Pacheco, J., Pai, A., Palomba, C., Paoletti, F., Paoli, A., Paoli, L., Pasqualetti, A., Passaquieti, R, Passuello, D., Perciballi, M., Peruzzi, S., Perniola, B., Pinard, L., Poggiani, R., Popolizio, P., Porter, E., Puccinelli, S., Punturo, M., Puppo, P., Qipiani, K., Ramonet, J., Rapagnani, Piero, Reita, V., Remillieux, A., Ricci, Fulvio, Richard, F., Roger, J. P., Ruggi, P., Russo, G., Solimeno, S., Stanga, R., Taddei, R., Teuler, J. M., Tournefier, E., Travasso, F., Trinquet, H., Turri, E., Varvella, M., Verkindt, D., Vetrano, F., Veziant, O., Viceré, A., Vilalte, S., Vinet, J. Y., Vocca, H., Yvert, M, and Zhang, Z.

Published
2003

18. Data analysis methods for non-gaussian, nonstationary; nonlinear features; their application to VIRGO

Author

Acernese, F., Amico, P., Arnaud, N., Babusci, D., Ballardin, G., Barillé, R., Barone, F., Barsuglia, M., Beauville, F., Bellachia, F., Bizouard, M. A., Boccara, C., Boget, D., Bondu, F., Bourgoin, C., Bozzi, A., Braccini, S., Bradaschia, C., Brillet, A., Brisson, V., Brocco, L., Buskulic, D., Cachenaut, J., Calamai, G., Calloni, E., Campagna, E., Casciano, C., Cattuto, C., Cavalier, F., Cavaliere, S., Cavalieri, R., Cella, G., Chassande Mottin, E., Chollet, F., Cleva, F., Cokelaer, T., Conforto, G., Cortese, S., Coulon, J. P., Cuoco, E., Dattilo, V., Davíd, P. Y., Davier, M., de Rosa, M., de Rosa, R., di Fiore, L., di Virgilio, A., Dujardin, B., Dominici, P., Eleuteri, A., Enard, D., Evangelista, G., Ferrante, I., Fidecaro, F., Fiori, I., Flaminio, R., Forest, D., Fournier, J. D., Fournier, L., Frasca, Sergio, Frasconi, F., Gammaitoni, L., Ganau, P., Gennai, A., Gennaro, G., Giacobone, L., Giazotto, A., Giordano, G., Girard, C., Gougoulat, G., Guidi, G. M., Heitmann, H., Hello, P., Hermel, R., Heusse, P., Holloway, L., Honglie, F., Iannarelli, M., Journet, L., Krecklbergh, S., Lagrange, B., la Penna, P., Leliboux, M., Lieunard, B., Lomtadze, T., Loriette, V., Losurdo, G., Loupias, M., Mackowski, J. M., Majorana, E., Man, C. N., Marchesoni, F., Marion, F., Martelli, F., Masserot, A., Massonnet, L., Mataguez, S., Menzinger, F., Mazzoni, M., Michel, C., Milano, L., Montorio, J. L., Moreau, F., Moreau, J., Morgado, N., Mornet, F., Mours, B., Mugnier, P., Nenci, F., Pacheco, J., Pai, A., Palomba, C., Paoletti, F., Paoli, A., Paoli, L., Pasqualetti, A., Passaquieti, R., Passuello, D., Perciballi, M., Peruzzi, S., Perniola, B., Pinard, L., Poggiani, R., Popolizio, P., Porter, E., Puccinelli, S., Punturo, M., Puppo, P., Qipiani, K., Ramonet, J., Rapagnani, Piero, Reita, V., Remillieux, A., Ricci, Fulvio, Richard, F., Roger, J. P., Ruggi, P., Russo, G., Solimeno, S., Stanga, R., Taddei, R., Teuler, J. M., Tournefier, E., Travasso, F., Trinquet, H., Turri, E., Varvella, M., Verkindt, D., Vetrano, F., Veziant, O., Viceré, A., Vilalte, S., Vinet, J. Y., Vocca, H., Yvert, M., and Zhang, Z.

Subjects
analisi dati, interferometri, Onde gravitazionali
Published
2003

28. Inducible Expression of Active Protein Phosphatase-1 Inhibitor-1 Enhances Basal Cardiac Function and Protects Against Ischemia/Reperfusion Injury.

Author

Nicolaou, Persoulla, Rodriguez, Patricia, Ren, Xiapong, Zhou, Xiaoyang, Qian, Jiang, Sadayappan, Sakthivel, Mitton, Bryan, Pathak, Anand, Robbins, Jeffrey, Hajjar, Roger J., Jones, Keith, and Kranias, Evangelista G.

Subjects
PHOSPHOPROTEIN phosphatases, MYOCARDIAL infarction, ISCHEMIA, SARCOPLASMIC reticulum, REPERFUSION injury, LABORATORY mice
Abstract

The article focuses on a study on the effect of active protein phosphatase-1inhibitor-1(I-1) on basal cardiac function and schemia/reperfusion injury through a mouse model. It states that I-1 activity has enhanced contractile function and sarcoplasmic reticulum Ca 2+ transport. Further, a phosphoproteomic analysis reveals that I-1 activity has contracted the recovery of ischemia/reperfusion injury. It suggests that I-1 activity can be a therapeutic strategy in myocardial infarction.

Published
2009
Full Text
View/download PDF

29. The Virgo data acquisition system

Author

Acernese, F., Amico, P., Arnaud, N., Arnault, C., Babusci, D., Ballardin, G., Barone, F., Barsuglia, M., Bellachia, F., Beney, J. L., Bilhaut, R., Bizouard, M. A., Bizzarri, R., Boccara, C., Boget, D., François Bondu, Bourgoin, C., Bozzi, A., Bracci, L., Braccini, S., Bradaschia, C., Brillet, A., Brisson, V., Brocco, L., Buskulic, D., Cachenaut, J., Calamai, G., Calloni, E., Canitrot, P., Cattuto, C., Cavalier, F., Cavaliere, S., Cavalieri, R., Cecchi, R., Cella, G., Chassande-Mottin, E., Chiche, R., François Chollet, Cleva, F., Cokelaer, T., Conforto, G., Cortese, S., Coulon, J. P., Cuoco, E., Cuzon, S., Dattilo, V., David, P. Y., Davier, M., Rosa, M., Rosa, R., Dehamme, M., Di Fiore, L., Di Virgilio, A., Dominici, P., Dufournaud, D., Eder, C., Eleuteri, A., Enard, D., Evangelista, G., Fabbroni, L., Ferrante, I., Fidecaro, F., Flaminio, R., Forest, D., Fournier, J. D., Fournier, L., Frasca, S., Frasconi, F., Gammaitoni, L., Ganau, P., Gaspard, M., Gennaro, G., Giacobone, L., Giazotto, A., Giordano, G., Christian Girard, Guidi, G., Heitmann, H., Hello, P., Hermel, R., Heusse, P., Holloway, L., Honglie, F., Iannarelli, M., Innocent, J. M., Jules, E., Kaczmarska, A., Rédha kassi, La Penna, P., Lagrange, B., Leliboux, M., Lieunard, B., Lodygenski, O., Lomtadze, T., Loriette, V., Losurdo, G., Loupias, M., M Mackowski, J., Majorana, E., Man, C. N., Mansoux, B., Marchesoni, F., Pierre Marin, Marion, F., Marrucho, J. C., Martelli, F., Masserot, A., Massonnet, L., Mataguez, S., Mazzoni, M., Mencik, M., Christine Michel, Milano, L., L Montorio, J., Moreau, F., Morgado, N., Mours, B., Mugnier, P., Nenci, F., Nicolosi, L., Pacheco, J., Pai, A., Palomba, C., Paoletti, F., Paoli, A., Pasqualetti, A., Passaquieti, R., Passuello, D., Perciballi, M., Pinard, L., Poggiani, R., Popolizio, P., Porter, E., Punturo, M., Puppo, P., Qipiani, K., Ramonet, J., Rapagnani, P., Reboux, A., Regimbau, T., Reita, V., Remillieux, A., Ricci, F., Ripepe, M., Rivoirard, P., Roger, J. P., Russo, G., Scheidecker, J. P., Solimeno, S., Stanga, R., Taddei, R., Taurigna, M., Teuler, J. M., Tournefier, E., Tourrenc, P., Trinquet, H., Turri, E., Varvella, M., Verkindt, D., Vetrano, F., Veziant, O., Vicere, A., Vilalte, S., Vinet, J. Y., Vocca, H., Yvert, M., Zhen Zhang, Richard, F., Laboratoire de l'Accélérateur Linéaire (LAL), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Annecy de Physique des Particules (LAPP/Laboratoire d'Annecy-le-Vieux de Physique des Particules), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Astrophysique Relativiste Théories Expériences Métrologie Instrumentation Signaux (ARTEMIS), Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Institut de Physique Nucléaire de Lyon (IPNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), VIRGO, Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), Laboratoire d'Annecy de Physique des Particules (LAPP), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), and BOMBAR, Claudine

Subjects
[PHYS.PHYS.PHYS-INS-DET] Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det], [PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

30. Editorial

Author

Kahrs Mark, Bacry Emmanuel, and Evangelista Gianpaolo

Subjects
Telecommunication, TK5101-6720, Electronics, TK7800-8360
Published
2003
Full Text
View/download PDF

31. Audio Effects Based on Biorthogonal Time-Varying Frequency Warping

Author

Cavaliere Sergio and Evangelista Gianpaolo

Subjects
signal transformations, frequency warping, Laguerre transform, Kautz functions, Telecommunication, TK5101-6720, Electronics, TK7800-8360
Abstract

We illustrate the mathematical background and musical use of a class of audio effects based on frequency warping. These effects alter the frequency content of a signal via spectral mapping. They can be implemented in dispersive tapped delay lines based on a chain of all-pass filters. In a homogeneous line with first-order all-pass sections, the signal formed by the output samples at a given time is related to the input via the Laguerre transform. However, most musical signals require a time-varying frequency modification in order to be properly processed. Vibrato in musical instruments or voice intonation in the case of vocal sounds may be modeled as small and slow pitch variations. Simulation of these effects requires techniques for time-varying pitch and/or brightness modification that are very useful for sound processing. The basis for time-varying frequency warping is a time-varying version of the Laguerre transformation. The corresponding implementation structure is obtained as a dispersive tapped delay line, where each of the frequency dependent delay element has its own phase response. Thus, time-varying warping results in a space-varying, inhomogeneous, propagation structure. We show that time-varying frequency warping is associated to an expansion over biorthogonal sets generalizing the discrete Laguerre basis. Slow time-varying characteristics lead to slowly varying parameter sequences. The corresponding sound transformation does not suffer from discontinuities typical of delay lines based on unit delays.

Published
2001
Full Text
View/download PDF

32. Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST)

Author

Simona Lattanzi, Laura Canafoglia, Maria Paola Canevini, Sara Casciato, Emanuele Cerulli Irelli, Valentina Chiesa, Filippo Dainese, Giovanni De Maria, Giuseppe Didato, Giancarlo Di Gennaro, Giovanni Falcicchio, Martina Fanella, Edoardo Ferlazzo, Massimo Gangitano, Angela La Neve, Oriano Mecarelli, Elisa Montalenti, Alessandra Morano, Federico Piazza, Chiara Pizzanelli, Patrizia Pulitano, Federica Ranzato, Eleonora Rosati, Laura Tassi, Carlo Di Bonaventura, Angela Alicino, Michele Ascoli, Giovanni Assenza, Federica Avorio, Valeria Badioni, Paola Banfi, Emanuele Bartolini, Luca Manfredi Basili, Vincenzo Belcastro, Simone Beretta, Irene Berto, Martina Biggi, Giuseppe Billo, Giovanni Boero, Paolo Bonanni, Jole Bongorno, Francesco Brigo, Emanuele Caggia, Claudia Cagnetti, Carmen Calvello, Edward Cesnik, Gigliola Chianale, Domenico Ciampanelli, Roberta Ciuffini, Dario Cocito, Donato Colella, Margerita Contento, Cinzia Costa, Eduardo Cumbo, Alfredo D'Aniello, Francesco Deleo, Jacopo C DiFrancesco, Roberta Di Giacomo, Alessandra Di Liberto, Elisabetta Domina, Fedele Dono, Vania Durante, Maurizio Elia, Anna Estraneo, Giacomo Evangelista, Maria Teresa Faedda, Ylenia Failli, Elisa Fallica, Jinane Fattouch, Alessandra Ferrari, Florinda Ferreri, Giacomo Fisco, Davide Fonti, Francesco Fortunato, Nicoletta Foschi, Teresa Francavilla, Rosita Galli, Stefano Gazzina, Anna Teresa Giallonardo, Filippo Sean Giorgi, Loretta Giuliano, Francesco Habetswallner, Francesca Izzi, Benedetta Kassabian, Angelo Labate, Concetta Luisi, Matteo Magliani, Giulia Maira, Luisa Mari, Daniela Marino, Addolorata Mascia, Alessandra Mazzeo, Chiara Milano, Stefano Meletti, Annacarmen Nilo, Biagio Orlando, Francesco Paladin, Maria Grazia Pascarella, Chiara Pastori, Giada Pauletto, Alessia Peretti, Gabriella Perri, Marianna Pezzella, Marta Piccioli, Pietro Pignatta, Nicola Pilolli, Francesco Pisani, Laura Rosa Pisani, Fabio Placidi, Patrizia Pollicino, Vittoria Porcella, Silvia Pradella, Monica Puligheddu, Stefano Quadri, Pier Paolo Quarato, Rui Quintas, Rosaria Renna, Giada Ricciardo Rizzo, Adriana Rum, Enrico Michele Salamone, Ersilia Savastano, Maria Sessa, David Stokelj, Elena Tartara, Mario Tombini, Gemma Tumminelli, Anna Elisabetta Vaudano, Maria Ventura, Ilaria Viganò, Emanuela Viglietta, Aglaia Vignoli, Flavio Villani, Elena Zambrelli, Lelia Zummo, Lattanzi S., Canafoglia L., Canevini M.P., Casciato S., Cerulli Irelli E., Chiesa V., Dainese F., De Maria G., Didato G., Di Gennaro G., Falcicchio G., Fanella M., Ferlazzo E., Gangitano M., La Neve A., Mecarelli O., Montalenti E., Morano A., Piazza F., Pizzanelli C., Pulitano P., Ranzato F., Rosati E., Tassi L., Di Bonaventura C., Alicino A., Ascoli M., Assenza G., Avorio F., Badioni V., Banfi P., Bartolini E., Basili L.M., Belcastro V., Beretta S., Berto I., Biggi M., Billo G., Boero G., Bonanni P., Bongiorno J., Brigo F., Caggia E., Cagnetti C., Calvello C., Cesnik E., Chianale G., Ciampanelli D., Ciuffini R., Cocito D., Colella D., Contento M., Costa C., Cumbo E., D'Aniello A., Deleo F., DiFrancesco J.C., Di Giacomo R., Di Liberto A., Domina E., Dono F., Durante V., Elia M., Estraneo A., Evangelista G., Faedda M.T., Failli Y., Fallica E., Fattouch J., Ferrari A., Ferreri F., Fisco G., Fonti D., Fortunato F., Foschi N., Francavilla T., Galli R., Gazzina S., Giallonardo A.T., Giorgi F.S., Giuliano L., Habetswallner F., Izzi F., Kassabian B., Labate A., Luisi C., Magliani M., Maira G., Mari L., Marino D., Mascia A., Mazzeo A., Milano C., Meletti S., Nilo A., Orlando B., Paladin F., Pascarella M.G., Pastori C., Pauletto G., Peretti A., Perri G., Pezzella M., Piccioli M., Pignatta P., Pilolli N., Pisani F., Pisani L.R., Placidi F., Pollicino P., Porcella V., Pradella S., Puligheddu M., Quadri S., Quarato P.P., Quintas R., Renna R., Rizzo G.R., Rum A., Salamone E.M., Savastano E., Sessa M., Stokelj D., Tartara E., Tombini M., Tumminelli G., Vaudano A.E., Ventura M., Vigano I., Viglietta E., Vignoli A., Villani F., Zambrelli E., and Zummo L.

Subjects
Adult, Antiseizure medication, Brivaracetam, Cerebrovascular diseases, Focal seizures, Stroke, Settore MED/26, Antiseizure medication, Brivaracetam, Focal seizures, Stroke, Cerebrovascular diseases, Double-Blind Method, Drug Therapy, Seizures, Humans, Aged, Retrospective Studies, Epilepsy, General Medicine, Middle Aged, Pyrrolidinones, Treatment Outcome, Neurology, Italy, Combination, Anticonvulsants, Drug Therapy, Combination, Neurology (clinical)
Abstract

Objective: Post-stroke epilepsy (PSE) is one of the most common causes of acquired epilepsy and accounts for about 10-15% of all newly diagnosed epilepsy cases. However, evidence about the clinical profile of antiseizure medications in the PSE setting is currently limited. Brivaracetam (BRV) is a rationally developed compound characterized by high-affinity binding to synaptic vesicle protein 2A. The aim of this study was to assess the 12-month effectiveness and tolerability of adjunctive BRV in patients with PSE treated in a real-world setting. Methods: This was a subgroup analysis of patients with PSE included in the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). The BRIVAFIRST was a 12-month retrospective, multicentre study including adult patients prescribed adjunctive BRV. Effectiveness outcomes included the rates of seizure response (≥50% reduction in baseline seizure frequency), seizure‐freedom, and treatment discontinuation. Safety and tolerability outcomes included the rate of treatment discontinuation due to adverse events (AEs) and the incidence of AEs. Results: Patients with PSE included in the BRIVAFIRST were 75 and had a median age of 57 (interquartile range, 42-66) years. The median daily doses of BRV at 3, 6, and 12 months from starting treatment were 100 (100-150) mg, 125 (100-200) mg and 100 (100-200) mg, respectively. At 12 months, 32 (42.7%) patients had a reduction in their baseline seizure frequency by at least 50%, and the seizure freedom rates was 26/75 (34.7%). During the 1-year study period, 10 (13.3%) patients discontinued BRV. The reasons of treatment withdrawal were insufficient efficacy in 6 (8.0%) patients and poor tolerability in 4 (5.3%) patients. Adverse events were reported by 13 (20.3%) patients and were rated as mild in 84.6% and moderate in 15.4% of cases. Significance: Adjunctive BRV was efficacious and generally well-tolerated when used in patients with PSE in clinical practice. Adjunctive BRV can be a suitable therapeutic option for patients with PSE.

Published
2022

33. Radiosensitizing effect of curcumin-loaded lipid nanoparticles in breast cancer cells

Author

Giorgio Ivan Russo, Francesco Paolo Cammarata, Marcella Bonanomi, Daniela Gaglio, Carmelo Militello, Maria Carla Gilardi, Nunziatina Porcino, Margherita Baglio, G. Evangelista, Gaetano Savoca, B. Abbate, G. Iacoviello, Erika Amore, Giusi Irma Forte, Luigi Minafra, Valentina Bravatà, Maria Luisa Bondì, Minafra, L, Porcino, N, Bravatà, V, Gaglio, D, Bonanomi, M, Amore, E, Cammarata, F, Russo, G, Militello, C, Savoca, G, Baglio, M, Abbate, B, Iacoviello, G, Evangelista, G, Gilardi, M, Bondì, M, and Forte, G

Subjects
0301 basic medicine, Radiation-Sensitizing Agents, Radiosensitizer, Curcumin, Cell Survival, medicine.medical_treatment, lcsh:Medicine, Antineoplastic Agents, Apoptosis, Breast Neoplasms, Article, 03 medical and health sciences, chemistry.chemical_compound, Drug Delivery Systems, 0302 clinical medicine, Cell Line, Tumor, medicine, Humans, Radiosensitivity, Particle Size, Clonogenic assay, lcsh:Science, IC50, Drug Carriers, Multidisciplinary, Radiotherapy, Chemistry, lcsh:R, Radiotherapy, Systems biology, Lipids, In vitro, Radiation therapy, 030104 developmental biology, Cancer cell, MCF-7 Cells, Cancer research, Nanoparticles, Female, lcsh:Q, Systems biology, 030217 neurology & neurosurgery
Abstract

In breast cancer (BC) care, radiotherapy is considered an efficient treatment, prescribed both for controlling localized tumors or as a therapeutic option in case of inoperable, incompletely resected or recurrent tumors. However, approximately 90% of BC-related deaths are due to the metastatic tumor progression. Then, it is strongly desirable to improve tumor radiosensitivity using molecules with synergistic action. The main aim of this study is to develop curcumin-loaded solid nanoparticles (Cur-SLN) in order to increase curcumin bioavailability and to evaluate their radiosensitizing ability in comparison to free curcumin (free-Cur), by using an in vitro approach on BC cell lines. In addition, transcriptomic and metabolomic profiles, induced by Cur-SLN treatments, highlighted networks involved in this radiosensitization ability. The non tumorigenic MCF10A and the tumorigenic MCF7 and MDA-MB-231 BC cell lines were used. Curcumin-loaded solid nanoparticles were prepared using ethanolic precipitation and the loading capacity was evaluated by UV spectrophotometer analysis. Cell survival after treatments was evaluated by clonogenic assay. Dose–response curves were generated testing three concentrations of free-Cur and Cur-SLN in combination with increasing doses of IR (2–9 Gy). IC50 value and Dose Modifying Factor (DMF) was measured to quantify the sensitivity to curcumin and to combined treatments. A multi-“omic” approach was used to explain the Cur-SLN radiosensitizer effect by microarray and metobolomic analysis. We have shown the efficacy of the Cur-SLN formulation as radiosensitizer on three BC cell lines. The DMFs values, calculated at the isoeffect of SF = 50%, showed that the Luminal A MCF7 resulted sensitive to the combined treatments using increasing concentration of vehicled curcumin Cur-SLN (DMF: 1,78 with 10 µM Cur-SLN.) Instead, triple negative MDA-MB-231 cells were more sensitive to free-Cur, although these cells also receive a radiosensitization effect by combination with Cur-SLN (DMF: 1.38 with 10 µM Cur-SLN). The Cur-SLN radiosensitizing function, evaluated by transcriptomic and metabolomic approach, revealed anti-oxidant and anti-tumor effects. Curcumin loaded- SLN can be suggested in future preclinical and clinical studies to test its concomitant use during radiotherapy treatments with the double implications of being a radiosensitizing molecule against cancer cells, with a protective role against IR side effects.

Published
2019
Full Text
View/download PDF

34. Interictal Heart Rate Variability Analysis Reveals Lateralization of Cardiac Autonomic Control in Temporal Lobe Epilepsy

Author

Fedele Dono, Giacomo Evangelista, Valerio Frazzini, Catello Vollono, Claudia Carrarini, Mirella Russo, Camilla Ferrante, Vincenzo Di Stefano, Luciano P. Marchionno, Maria V. De Angelis, Massimiliano Faustino, Laura Bonanni, Marco Onofrj, Stefano L. Sensi, Francesca Anzellotti, Università degli studi 'G. d'Annunzio' Chieti-Pescara [Chieti-Pescara] (Ud'A), Unité fonctionnelle d'épilepsie [CHU Pitié-Salpêtrière], Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-IFR70-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Università degli studi di Palermo - University of Palermo, Dono F., Evangelista G., Frazzini V., Vollono C., Carrarini C., Russo M., Ferrante C., Di Stefano V., Marchionno L.P., De Angelis M.V., Faustino M., Bonanni L., Onofrj M., Sensi S.L., Anzellotti F., Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-IFR70-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)

Subjects
cardiovascular risk, medicine.medical_specialty, 030204 cardiovascular system & hematology, Sudden death, interictal epileptic discharge, behavioral disciplines and activities, interictal epileptic discharges, lcsh:RC346-429, Temporal lobe, 03 medical and health sciences, Epilepsy, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, Heart rate, medicine, Heart rate variability, Ictal, lcsh:Neurology. Diseases of the nervous system, Original Research, business.industry, Seizure types, autonomic nervous system, heart rate variability, temporal lobe epilepsy, medicine.disease, nervous system diseases, Autonomic nervous system, Neurology, Cardiology, Settore MED/26 - Neurologia, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Neurology (clinical), business, 030217 neurology & neurosurgery
Abstract

International audience; Purpose: The temporal lobe, a critical hub for cognition, also plays a central role in the regulation of autonomic cardiovascular functions. Lesions in this area are usually associated with abnormalities in the regulation of heart rate (HR) and blood pressure (BP). The analysis of the heart rate variability (HRV) is useful to evaluate the cardiac parasympathetic nervous system activity. This study aims at comparing HRV changes occurring in two groups of patients suffering from Temporal Lobe Epilepsy (TLE). To that aim, we evaluated patients differentiated by the right or left location of the epileptic foci. Materials and Methods: Fifty-two adult patients with a diagnosis of TLE were enrolled. Each patient underwent a 20-min EEG + EKG recording in resting state. According to the localization of epileptic focus, patients were divided into two subgroups: right TLE (R-TLE) and left TLE (L-TLE). HRV parameters were calculated with a short-lasting analysis of EKG recordings. Time-domain and frequency domain-related, as well as non-linear analysis, parameters, were compared between the two groups. Results: Compared to the R-TLE group, L-TLE subjects showed a significant decrease in low frequency (LF) (p < 0.01) and low frequency/high-frequency ratio (LF/HF) (p < 0.001) as well as increased HF values (p < 0.01), a parameter indicative of the presence of an increased cardiac vagal tone. These results were also confirmed in the subgroup analysis that took into account the seizure types, responses to antiepileptic drugs, seizure frequencies, and etiology. Conclusions: The main finding of the study is that, compared to R-TLE, L-TLE is associated with increased cardiac vagal tone. These results indicate that patients with TLE exhibit a lateralized cardiac autonomic control. L-TLE patients may have a lower risk of developing cardiac dysfunctions and less susceptible to develop Sudden Death for Epilepsy (SUDEP).

Published
2019
Full Text
View/download PDF

35. In silico Structural Study of Random Amino Acid Sequence Proteins Not Present in Nature

Author

Zdzisław Wiśniowski, Fabio Polticelli, Monika Piwowar, Kinga Sałapa, Marek Kochańczyk, Maciej Malawski, Tomasz Szepieniec, Lukasz Flis, Giuseppe Minervini, Irena Roterman, Giovanni Evangelista, Katarzyna Prymula, Ewa Matczyńska, Prymula, K, Piwowar, M, Kochanczyk, M, Flis, L, Malawski, M, Szepieniec, T, Evangelista, G, Minervini, G, Polticelli, Fabio, Wisniowski, Z, Salapa, K, Matczynska, E, and Roterman, I.

Subjects
Models, Molecular, Protein Structure, Secondary, Structural similarity, In silico, Molecular Sequence Data, Bioengineering, Computational biology, Biochemistry, Protein Structure, Secondary, Protein sequencing, Protein structure, Models, Algorithms, Amino Acid Sequence, Catalytic Domain, Proteins, Molecular Biology, Peptide sequence, chemistry.chemical_classification, Molecular, General Chemistry, General Medicine, Structural Classification of Proteins database, Amino acid, chemistry, Molecular Medicine, Threading (protein sequence)
Abstract

f ),Zdzislaw Wisniowski a ),Kinga Salapa a a ) 1 ) a The three-dimensional structures of a set ofnever born proteins� (NBP, random amino acid sequence proteins with no significant homology with known proteins) were predicted using two methods: Rosetta and the one based on thefuzzy-oil-drop� (FOD) model. More than 3000 different random amino acid sequences have been generated, filtered against the non redundant protein sequence data base, to remove sequences with significant homology with known proteins, and subjected to three- dimensional structure prediction. Comparison between Rosetta and FOD predictions allowed to select the ten top (highest structural similarity) and the ten bottom (the lowest structural similarity) structures from the ranking list organized according to the RMS-D value. The selected structures were taken for detailed analysis to define the scale of structural accordance and discrepancy between the two methods. The structural similarity measurements revealed discrepancies between structures generated on the basis of the two methods. Their potential biological function appeared to be quite different as well. The ten bottom structures appeared to beunfoldablefor the FOD model. Some aspects of the general characteristics of the NBPs are also discussed. The calculations were performed on the EUChinaGRID grid platform to test the performance of this infrastructure for massive protein structure predictions. Introduction. - The search for techniques aimed at the generation of new proteins for pharmacological and biotechnological applications is widely developed nowadays (1 - 3). This involves the selection of proteins of desirable activity among those present in Nature, as well as the production of new polypeptide compounds resulting from libraries of peptides with random amino acid sequences (4) (5). The final aim of these

Published
2009
Full Text
View/download PDF

36. Massive non-natural proteins structure prediction using grid technologies

Author

Giuseppe Evangelista, Fabio Polticelli, Debora Slanzi, Giovanni Minervini, Pier Luigi Luisi, Irene Poli, Davide De Lucrezia, Laura Villanova, Minervini, G, Evangelista, G, Villanova, L, Slanzi, D, DE LUCREZIA, D, Poli, I, Luisi, Pl, and Polticelli, Fabio

Subjects
Computational biology, Biology, Biochemistry, Natural (archaeology), Databases, Protein structure, Structural Biology, Sequence Analysis, Protein, Feature (machine learning), Amino Acid Sequence, Databases, Protein, Computational Biology, Proteins, Molecular Biology, Genetics, Applied Mathematics, Protein, Protein structure prediction, Grid, Computer Science Applications, Proceedings, Amino acid composition, Product (mathematics), Settore SECS-S/01 - Statistica, Sequence Analysis
Abstract

Background The number of natural proteins represents a small fraction of all the possible protein sequences and there is an enormous number of proteins never sampled by nature, the so called "never born proteins" (NBPs). A fundamental question in this regard is if the ensemble of natural proteins possesses peculiar chemical and physical properties or if it is just the product of contingency coupled to functional selection. A key feature of natural proteins is their ability to form a well defined three-dimensional structure. Thus, the structural study of NBPs can help to understand if natural protein sequences were selected for their peculiar properties or if they are just one of the possible stable and functional ensembles. Methods The structural characterization of a huge number of random proteins cannot be approached experimentally, thus the problem has been tackled using a computational approach. A large random protein sequences library (2 × 104 sequences) was generated, discarding amino acid sequences with significant similarity to natural proteins, and the corresponding structures were predicted using Rosetta. Given the highly computational demanding problem, Rosetta was ported in grid and a user friendly job submission environment was developed within the GENIUS Grid Portal. Protein structures generated were analysed in terms of net charge, secondary structure content, surface/volume ratio, hydrophobic core composition, etc. Results The vast majority of NBPs, according to the Rosetta model, are characterized by a compact three-dimensional structure with a high secondary structure content. Structure compactness and surface polarity are comparable to those of natural proteins, suggesting similar stability and solubility. Deviations are observed in α helix-β strands relative content and in hydrophobic core composition, as NBPs appear to be richer in helical structure and aromatic amino acids with respect to natural proteins. Conclusion The results obtained suggest that the ability to form a compact, ordered and water-soluble structure is an intrinsic property of polypeptides. The tendency of random sequences to adopt α helical folds indicate that all-α proteins may have emerged early in pre-biotic evolution. Further, the lower percentage of aromatic residues observed in natural proteins has important evolutionary implications as far as tolerance to mutations is concerned.

Full Text
View/download PDF

37. Autoimmune encephalitis during pregnancy: A diagnostic and therapeutic challenge-A systematic review with individual patients' analysis and clinical recommendations.

Author

Dono F, Consoli S, Tappatà M, Evangelista G, Russo M, Lanzone J, Pozzilli V, Nucera B, Rinaldi F, Di Pietro M, Tinti L, Troisi S, Calisi D, D'Apolito M, Narducci F, Assenza G, Anzellotti F, Brigo F, Vollono C, Onofrj M, Sensi SL, and Michelucci R

Subjects
Humans, Pregnancy, Female, Cesarean Section, Encephalitis diagnosis, Encephalitis therapy, Abortion, Spontaneous, Autoimmune Diseases of the Nervous System
Abstract

Several reports have described the autoimmune encephalitis' (AE) possible onset during pregnancy. In this systematic review, we summarize the available data on the diagnostic and therapeutic approach to AE during pregnancy, highlighting the associated maternal and fetal clinical outcomes. A systematic search of the literature was performed. The following databases were used: PubMed, Google Scholar, EMBASE, and CrossRef. The revision was registered on the PROSPERO platform (CRD42022336357). Forty-nine patients were included. AE onset was mainly observed during the first and the second trimester of pregnancy with psychiatric manifestations and seizures as main onset symptoms. CSF analysis showed AE-specific autoantibody positivity in 33 patients (anti-NMDA receptor as the most frequent). EEG generally showed normal findings. MRI revealed pathological findings in less than half of patients. Tumor screening was positive in 14 cases. First-line immunotherapy (single or combined) was generally employed while second line was administered in a minority of patients. Levetiracetam was the most used antiseizure medication. Cesarean section was performed in 18 women. Most of the women had an excellent early outcome after delivery but 22 showed persistent neurological deficits in long-term follow-up. Fetal outcome was positive in 33 cases, whereas 12 cases of fetal death were reported. A logistic regression showed that no variable significantly influenced the odds of good/bad maternal and fetal clinical outcome. Diagnosis and treatment of AE during pregnancy is challenging. The rate of miscarriage in women with AE seems to be higher than the general population. In addition, mothers may show long-term neurological deficits., (© 2023 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.)

Published
2023
Full Text
View/download PDF

38. SARM1 deletion delays cerebellar but not spinal cord degeneration in an enhanced mouse model of SPG7 deficiency.

Author

Montoro-Gámez C, Nolte H, Molinié T, Evangelista G, Tröder SE, Barth E, Popovic M, Trifunovic A, Zevnik B, Langer T, and Rugarli EI

Subjects
Animals, Humans, Mice, Armadillo Domain Proteins genetics, ATPases Associated with Diverse Cellular Activities, Axons pathology, Cerebellum, Cytoskeletal Proteins genetics, Metalloendopeptidases genetics, Metalloendopeptidases metabolism, NAD, Spastic Paraplegia, Hereditary genetics
Abstract

Hereditary spastic paraplegia is a neurological condition characterized by predominant axonal degeneration in long spinal tracts, leading to weakness and spasticity in the lower limbs. The nicotinamide adenine dinucleotide (NAD+)-consuming enzyme SARM1 has emerged as a key executioner of axonal degeneration upon nerve transection and in some neuropathies. An increase in the nicotinamide mononucleotide/NAD+ ratio activates SARM1, causing catastrophic NAD+ depletion and axonal degeneration. However, the role of SARM1 in the pathogenesis of hereditary spastic paraplegia has not been investigated. Here, we report an enhanced mouse model for hereditary spastic paraplegia caused by mutations in SPG7. The eSpg7 knockout mouse carries a deletion in both Spg7 and Afg3l1, a redundant homologue expressed in mice but not in humans. The eSpg7 knockout mice recapitulate the phenotypic features of human patients, showing progressive symptoms of spastic-ataxia and degeneration of axons in the spinal cord as well as the cerebellum. We show that the lack of SPG7 rewires the mitochondrial proteome in both tissues, leading to an early onset decrease in mito-ribosomal subunits and a remodelling of mitochondrial solute carriers and transporters. To interrogate mechanisms leading to axonal degeneration in this mouse model, we explored the involvement of SARM1. Deletion of SARM1 delays the appearance of ataxic signs, rescues mitochondrial swelling and axonal degeneration of cerebellar granule cells and dampens neuroinflammation in the cerebellum. The loss of SARM1 also prevents endoplasmic reticulum abnormalities in long spinal cord axons, but does not halt the degeneration of these axons. Our data thus reveal a neuron-specific interplay between SARM1 and mitochondrial dysfunction caused by lack of SPG7 in hereditary spastic paraplegia., (© The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Published
2023
Full Text
View/download PDF

39. Case Report: Brain tumor's pitfalls: two cases of high-grade brain tumors mimicking autoimmune encephalitis with positive onconeuronal antibodies.

Author

Consoli S, Dono F, Evangelista G, Corniello C, Onofrj M, Thomas A, and Sensi SL

Abstract

Background: Glioblastoma (GBM) is the most common primary brain tumor in adulthood. Initial diagnosis is generally based on clinical and MRI findings, which may be misinterpreted as other neurological pictures, including autoimmune encephalitis (AE). AE is a heterogeneous group of neuroinflammatory diseases due to the presence of auto-antibodies targeting antigens on neuronal synaptic or cell surface. In the present report, we describe two peculiar cases of GBM initially misdiagnosed as AE, focusing on the diagnostic pitfalls and the treatment strategies., Methods: We report the case of two patients with high-grade brain tumors, initially misdiagnosed and treated for AE. Clinical, laboratory, and neuroradiological data are discussed in terms of differential diagnosis between AE and GBM., Results: The presence of atypical brain MRI findings and the unresponsiveness to immunosuppressive treatment are major red flags in the differential diagnosis between AE and GBM. In these cases, a brain biopsy is necessary to confirm the diagnosis., Conclusions: Atypical brain tumor presentation causes a diagnostic and therapeutic delay. A positive onconeural autoantibodies result should always be interpreted cautiously, considering the possibility of a false-positive test. A brain biopsy is mandatory for a definite diagnosis., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Consoli, Dono, Evangelista, Corniello, Onofrj, Thomas and Sensi.)

Published
2023
Full Text
View/download PDF

40. Diagnosis and treatment of late-onset myoclonic epilepsy in Down syndrome (LOMEDS): A systematic review with individual patients' data analysis.

Author

Corniello C, Dono F, Evangelista G, Consoli S, De Angelis S, Cipollone S, Liviello D, Polito G, Melchiorre S, Russo M, Granzotto A, Anzellotti F, Onofrj M, Thomas A, and Sensi SL

Subjects
Humans, Levetiracetam therapeutic use, Seizures diagnosis, Seizures etiology, Seizures therapy, Electroencephalography methods, Anticonvulsants therapeutic use, Down Syndrome complications, Down Syndrome drug therapy, Epilepsy drug therapy, Epilepsies, Myoclonic diagnosis, Epilepsies, Myoclonic drug therapy, Alzheimer Disease, Epilepsy, Generalized diagnosis, Epilepsy, Generalized drug therapy, Epilepsy, Generalized etiology
Abstract

Introduction: The late onset myoclonic epilepsy in Down Syndrome (LOMEDS) is a peculiar epilepsy type characterized by cortical myoclonus and generalized tonic-clonic seizures (GTCS), in people suffering from cognitive decline in Down syndrome (DS). In this review, we analyzed available data on the diagnostic and therapeutic management of individuals with LOMEDS., Methods: We performed a systematic search of the literature to identify the diagnostic and therapeutic management of patients with LOMEDS. The following databases were used: PubMed, Google Scholar, EMBASE, CrossRef. The protocol was registered on PROSPERO (registration code: CRD42023390748)., Results: Data from 46 patients were included. DS was diagnosed according to the patient's clinical and genetic characteristics. Diagnosis of Alzheimer's dementia (AD) preceded the onset of epilepsy in all cases. Both myoclonic seizures (MS) and generalized tonic-clonic seizures (GTCS) were reported, the latter preceding the onset of MS in 28 cases. EEG was performed in 45 patients, showing diffuse theta/delta slowing with superimposed generalized spike-and-wave or polyspike-and-wave. A diffuse cortical atrophy was detected in 34 patients on neuroimaging. Twenty-seven patients were treated with antiseizure medication (ASM) monotherapy, with reduced seizure frequency in 17 patients. Levetiracetam and valproic acid were the most used ASMs. Up to 41% of patients were unresponsive to first-line treatment and needed adjunctive therapy for seizure control., Conclusions: AD-related pathological changes in the brain may play a role in LOMEDS onset, although the mechanism underlying this phenomenon is still unknown. EEG remains the most relevant investigation to be performed. A significant percentage of patients developed a first-line ASM refractory epilepsy. ASMs which modulate the glutamatergic system may represent a good therapeutic option., Competing Interests: Declaration of Competing Interest Authors declare no conflicts of interest., (Copyright © 2023. Published by Elsevier Ltd.)

Published
2023
Full Text
View/download PDF

41. Sternal-Sparing Transapical, Beating Heart Mitral Valve Repair in an Adult With Repaired Tetralogy of Fallot.

Author

Gerosa G, D'Onofrio A, Evangelista G, Vida VL, and Pradegan N

Abstract

We present the case of a 60-year-old male patient who underwent tetralogy of Fallot repair at 7 years of age and then developed severe degenerative mitral regurgitation during adulthood. Given the increased surgical risk (obesity, obstructive sleep apnea syndrome, and reoperation), the patient underwent a successful microinvasive mitral valve repair with neochordae implantation. ( Level of Difficulty: Advanced. )., Competing Interests: The authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© 2023 Published by Elsevier on behalf of the American College of Cardiology Foundation.)

Published
2023
Full Text
View/download PDF

42. Standard versus rapid-deployment aortic valve replacement and concomitant myocardial revascularization: 5-year bi-centre clinical outcomes.

Author

Bottio T, Piperata A, Guariento A, Lorenzoni G, Cavicchiolo AG, Gemelli M, Pesce R, Evangelista G, Michelotti S, Gastino E, Gregori D, Ferrari E, and Gerosa G

Subjects
Aortic Valve surgery, Coronary Artery Bypass, Humans, Prosthesis Design, Treatment Outcome, Aortic Valve Stenosis surgery, Bioprosthesis adverse effects, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation adverse effects
Abstract

Objectives: Clinical outcomes of 2 generations of pericardial bioprostheses in concomitant aortic valve and coronary artery bypass graft surgery were analysed., Methods: Patients were recruited from 2 European centres and divided into 2 groups based on the type of aortic bioprosthesis used: Edwards Intuity Elite™ rapid-deployment (RD) bioprostheses or standard Edwards Magna Ease (ME). A propensity score weighting approach was used for data analysis., Results: A total of 285 patients were included: 144 (50.5%) in the RD group and 141 (49.5%) in the ME group. Thirty-day mortality was 2.8% (RD) and 5% (ME) (P = 0.09). Significantly shorter times of aortic cross-clamp and cardiopulmonary bypass were observed in the RD cohort [94 vs 120 min (P &lt; 0.001); 128 vs 160 min (P &lt; 0.001)]. The RD group was associated with a lower median transvalvular gradient at discharge and follow-up (both P &lt; 0.001). However, 5-year survival was not different, being 93% in RD patients and 91% in the ME group [hazard ratio 0.89 (95% confidence interval: 0.38-2.09), P = 0.784]. The 5-year cumulative incidence of combined events (including percutaneous coronary interventions, endocarditis, thromboembolic events, rehospitalizations and bleeding) favoured the ME group [16.1% (RD) vs 7.3% (ME)] [hazard ratio 2.38 (95% confidence interval:1.03-5.52), P = 0.043]. However, this turned similar when the Cox model analysis was adjusted for revascularization variables (P = 0.067)., Conclusions: RD and ME pericardial bioprostheses used in concomitant aortic valve replacement and coronary artery revascularization provide equivalent clinical and haemodynamic 5-year outcomes, despite constant lower transvalvular gradients and shorter surgical operating times observed with RD technology., (© The Author(s) 2022. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.)

Published
2022
Full Text
View/download PDF

43. Migraine Pharmacological Treatment and Cognitive Impairment: Risks and Benefits.

Author

Russo M, De Rosa MA, Calisi D, Consoli S, Evangelista G, Dono F, Santilli M, Granzotto A, Onofrj M, and Sensi SL

Subjects
Humans, Quality of Life, Risk Assessment, Cognition Disorders, Cognitive Dysfunction drug therapy, Cognitive Dysfunction etiology, Migraine Disorders drug therapy
Abstract

Migraine is a common neurological disorder impairing the quality of life of patients. The condition requires, as an acute or prophylactic line of intervention, the frequent use of drugs acting on the central nervous system (CNS). The long-term impact of these medications on cognition and neurodegeneration has never been consistently assessed. The paper reviews pharmacological migraine treatments and discusses their biological and clinical effects on the CNS. The different anti-migraine drugs show distinct profiles concerning neurodegeneration and the risk of cognitive deficits. These features should be carefully evaluated when prescribing a pharmacological treatment as many migraineurs are of scholar or working age and their performances may be affected by drug misuse. Thus, a reconsideration of therapy guidelines is warranted. Furthermore, since conflicting results have emerged in the relationship between migraine and dementia, future studies must consider present and past pharmacological regimens as potential confounding factors.

Published
2022
Full Text
View/download PDF

44. Vacuum-Implemented Removal of Lead Vegetations in Cardiac Device-Related Infective Endocarditis.

Author

Tarzia V, Ponzoni M, Evangelista G, Tessari C, Bertaglia E, De Lazzari M, Zanella F, Pittarello D, Migliore F, and Gerosa G

Abstract

When approaching infected lead removal in cardiac device-related infective endocarditis (CDRIE), a surgical consideration for large (>20 mm) vegetations is recommended. We report our experience with the removal of large CDRIE vegetations using the AngioVac system, as an alternative to conventional surgery. We retrospectively reviewed all infected lead extractions performed with a prior debulking using the AngioVac system, between October 2016 and April 2022 at our institution. A total of 13 patients presented a mean of 2(1) infected leads after a mean of 5.7(5.7) years from implantation (seven implantable cardioverter-defibrillators, four cardiac resynchronization therapy-defibrillators, and two pacemakers). The AngioVac system was used as a venous−venous bypass in six cases (46.2%), venous−venous ECMO-like circuit (with an oxygenator) in five (38.5%), and venous−arterial ECMO-like circuit in two cases (15.4%). Successful (>70%) aspiration of the vegetations was achieved in 12 patients (92.3%) and an intraoperative complication (cardiac perforation) only occurred in 1 case (7.7%). Subsequent lead extraction was successful in all cases, either manually (38.5%) or using mechanical tools (61.5%). The AngioVac system is a promising effective and safe option for large vegetation debulking in CDRIE. Planning the extracorporeal circuit design may represent the optimal strategy to enhance the tolerability of the procedure and minimize adverse events.

Published
2022
Full Text
View/download PDF

45. Perampanel enhances the cardiovagal tone and heart rate variability (HRV) in patients with drug-resistant temporal lobe epilepsy.

Author

Dono F, Evangelista G, Consoli S, Rodorigo D, Russo M, Carrarini C, Di Pietro M, De Angelis MV, Faustino M, Anzellotti F, Onofrj M, Di Iorio A, Sensi SL, Frazzini V, and Vollono C

Subjects
Adult, Heart Rate physiology, Humans, Nitriles, Pyridones, Seizures, Temporal Lobe, Drug Resistant Epilepsy drug therapy, Epilepsy, Temporal Lobe drug therapy, Sudden Unexpected Death in Epilepsy
Abstract

Objective: The temporal lobe plays a central role in the regulation of the "Central Autonomic Network" and cardiovascular functions. The blockade of glutamatergic pathways in the temporal lobe affects cardio-autonomic control. Perampanel (PER) is a non-competitive agonist of the AMPA receptor. This study evaluated PER effects on cardiac autonomic control in patients affected by drug-resistant TLE (DRTLE)., Methods: We enrolled 40 adults with DRTLE treated with PER as add-on therapy (PER group) and 32 DRTLE age, sex, and seizure-frequency matched controls treated with different additional anti-seizure medication (ASM) as add-on therapy (No-PER group). HRV analysis was performed on 5-minute EKG recording in resting state before and 6-months after the introduction of add-on ASM. Linear Mixed Models (LMM) were used to analyzed HRV variables according to time (baseline and 6-months follow-up) and groups., Results: At baseline no differences were detected between PER group and No-PER group according to time-domain and frequency-domain HRV parameters. At the follow-up, in PER group a multiplicative effect for the interaction between treatment and time was observed for MeanRR (ms) (p=0.03), LnRMSSD (ms) (p=0.04), LnHF (ms 2 ) (p<0.001), HF n.u. (p=0.001), HF% (p=0.002) with increased values, and for LnLF (ms 2 ) (p=0.001), LF n.u. (p=0.001), LF% (p=0.01), and LF/HF (p<0.001) with reduced values. The change in seizure frequency after add-on therapy was comparable between the two groups (p=0.81) CONCLUSIONS: Our data support the notion that PER increases the vagal tone in DRTLE. This activity may exert a cardioprotective effect by reducing the risk of developing cardiac arrhythmias. Furthermore, given the correlations between HRV modifications and the occurrence of SUDEP, future studies will need to test the protective effects of PER on SUDEP., (Copyright © 2022. Published by Elsevier Ltd.)

Published
2022
Full Text
View/download PDF

46. Non convulsive refractory status epilepticus induced by thiocolchicoside (TCC) intrathecal injection: A case report.

Author

Evangelista G, Dono F, Consoli S, Pozzilli V, Calisi D, Russo M, D'Orazio C, D'Andreagiovanni A, Montesano G, Rapini S, Caulo M, Onofrj M, and Anzellotti F

Subjects
Adult, Colchicine adverse effects, Colchicine analogs & derivatives, Electroencephalography, Female, Humans, Injections, Spinal adverse effects, Seizures drug therapy, Status Epilepticus chemically induced, Status Epilepticus complications, Status Epilepticus drug therapy
Abstract

TCC is a semisynthetic molecule widely used in clinical settings as a pain killer and myorelaxant. Several neurological side effects have been reported in association with TCC treatment including somnolence, confusion and seizure, the latter in a lower percentage of patients. Some previous reports described seizure onset after TCC intake in adulthood. However, major epileptological complication, namely status epilepticus, has never been previously reported in association with TCC treatment. In our report, we describe a case of acute refractory non-convulsive status epilepticus (NCSE) in the context of a TCC-induced acute toxic encephalopathy (ATE) in a woman without any previous neurological or physical comorbidities., (© 2022 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.)

Published
2022
Full Text
View/download PDF

47. Prevalence and Risk Factors of Bullying and Sexual and Racial Harassment in Healthcare Workers: A Cross-Sectional Study in Italy.

Author

La Torre G, Firenze A, Colaprico C, Ricci E, Di Gioia LP, Serò D, Perri G, Soncin M, Cremonesi D, De Camillis N, Guidolin S, Evangelista G, Marte M, Fedele NG, De Sio S, Mannocci A, Sernia S, and Brusaferro S

Subjects
Cross-Sectional Studies, Female, Health Personnel, Humans, Male, Prevalence, Risk Factors, Surveys and Questionnaires, Workplace, Bullying, Sexual Harassment, Workplace Violence
Abstract

Background: This cross-sectional study aims to evaluate the prevalence and socio-demographic factors associated with workplace bullying, sexual harassment and racial harassment among Italian health workers., Methods: We recruited 3129 participants using an online Italian translation of the 'Workplace Violence in the Health Sector Country Case Studies Research Instruments Survey' (WVHS) questionnaire. Data were analyzed with univariate (chi-square) and multivariate (multiple logistic regression) analysis., Results: Univariate analysis shows that females are significantly more affected by bullying (16.4% vs. 12.3%) and sexual harassment (2.4% vs. 1.3%). On the other hand, males are significantly more affected by racial harassment (3.1% vs. 2.0%). Multivariate analysis shows higher odds of being affected by bullying (OR = 1.30; 95% CI (1.03, 1.64)) and sexual harassment (OR = 2.08; 95% CI (1.04, 4.00)) for females, and higher odds of undergoing racial harassment (OR = 1.55; 95% CI (0.95, 2.53)) for males., Conclusion: This analysis of work situations looks to identify those risk factors, existing or potential, that increase the probability of episodes of violence. A group of work or other subjects identified by direction will have to evaluate the vulnerability of workplaces and establish more effective preventive actions to be adopted.

Published
2022
Full Text
View/download PDF

48. EEG Abnormalities During Delirium as a Prodromal Feature of Dementia with Lewy Bodies: A Case Report.

Author

Carrarini C, De Rosa MA, Calisi D, Digiovanni A, Salute P, Dono F, Evangelista G, Consoli S, Russo M, Ferri L, D'Ardes D, Mattoli MV, Cipollone F, Onofrj M, and Bonanni L

Abstract

Background: A 79-year-old woman was admitted to the Neurology Clinic of the University of Chieti-Pescara for a syncope. At admission, the occurrence of an acute stroke was ruled out. Her cognitive status was unimpaired. After three days from the hospitalization, the patient experienced an episode of mixed delirium., Objective: The present case report shows a case of delirium-onset dementia with Lewy bodies (DLB) with a specific electroencephalographic (EEG) pattern from its prodromal stage., Methods: Delirium was assessed by 4AT test. During the hospitalization, the patient underwent a quantitative EEG (QEEG) with spectral analysis. At six months from the episode of delirium, she was tested by neuropsychological evaluation, QEEG, and 18 F-fluorodeoxyglucose PET/CT to assess the onset of a possible cognitive decline., Results: At baseline, the QEEG exam showed a dominant frequency (DF) in the pre-alpha band (7.5 Hz) with a dominant frequency variability (DFV) of 2 Hz. This pattern is typical of DLB at early stage. After six months, she reported attention deficits in association with cognitive fluctuation and REM sleep behavior disorder. The neurological examination revealed signs of parkinsonism. Cognitive status resulted to be impaired (MoCA = 15/30). QEEG recording confirmed the presence of a DLB-typical pattern (DF = 7.5 Hz, DFV = 2.5 Hz). The 18 F-FDG-PET/CT showed a moderate bilateral posterior hypometabolism (occipital and temporal cortex), with relative sparing of the posterior cingulate cortex compared to cuneus/precuneus ( Cingulate Island sign ), and mild bilateral hypometabolism in frontal regions (suggestive of a DLB diagnosis)., Conclusion: EEGs may represent supportive and validated biomarkers for delirium-onset prodromal DLB., Competing Interests: The authors have no conflict of interest to report., (© 2022 – The authors. Published by IOS Press.)

Published
2022
Full Text
View/download PDF

49. Carpentier-Edwards Magna Ease bioprosthesis: a multicentre clinical experience and 12-year durability.

Author

Piperata A, Fiocco A, Cavicchiolo A, Ponzoni M, Pesce R, Gemelli M, Evangelista G, Gastino E, Michelotti S, Mazzaro E, Garufi L, DePaulis R, Zanella L, Nadali M, Mangino D, Lorenzoni G, Gregori D, Jorgji V, Gerosa G, and Bottio T

Subjects
Aortic Valve surgery, Follow-Up Studies, Humans, Prosthesis Design, Prosthesis Failure, Reoperation, Retrospective Studies, Bioprosthesis adverse effects, Heart Valve Prosthesis adverse effects, Heart Valve Prosthesis Implantation adverse effects, Heart Valve Prosthesis Implantation methods
Abstract

Objectives: The goal of this multicentre retrospective study was to compare long-term clinical and haemodynamic outcomes of the Carpentier-Edwards Magna Ease (CEME) bioprosthesis by patient age., Methods: We included consecutive patients who underwent isolated and combined surgical aortic valve replacement (AVR) with CEME valve between January 2008 and March 2020 at 4 cardiac surgery centres in Italy. Survival distribution was evaluated at follow-up according to age and surgery type (combined or isolated AVR), together with freedom from structural valve deterioration (SVD), reoperation and combined events, i.e. SVD, reoperation, endocarditis and thromboembolic events., Results: A total of 1027 isolated and 1121 combined AVR were included; 776 patients were younger than 65 years whereas 1372 were 65 years or older. The 30-day Valve-Academic-Research-Consortium mortality was 2% (<65 years) and 6% (≥ 65 years) (P < 0.001), whereas it was 3% for isolated AVR and 7% for combined AVR (P < 0.001). The 12-year survival was 81% for those younger than 65 years vs 45% for those equal to or older than 65 years (P < 0.001), whereas they were 61% vs 49% for isolated and combined AVR (P = 0.10). The 12-year freedom from combined events, excluding death, was 79% for those younger than 65 years vs 87% for those equal to or older than (P = 0.51), whereas they were 83% for isolated and 86% for combined AVR (P = 0.10). The 12-year freedom from SVD was 93% and 93% in patients younger than 65 and those equal to or older than 65 years (P = 0.63), and the results were comparable even in cases with isolated and combined AVR (92% vs 94%, P = 0.21). A multivariable Cox analysis including gender, presence of patient-prosthesis mismatch, isolated AVR and age showed that only the age was an independent risk factor for the incidence of SVD (P = 0.029)., Conclusions: Outcomes from this large multicentre analysis demonstrated that a CEME bioprosthesis provides good clinical results and long-term durability even in patients younger than 65 years. Furthermore, the hazard for SVD has been shown to be lower for older age., Clinical Trial Registration Number: 105n/AO/21., (© The Author(s) 2021. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.)

Published
2022
Full Text
View/download PDF

50. Anti N-methyl-D-aspartate receptor (NMDAr) encephalitis during pregnancy: A case report.

Author

Dono F, Evangelista G, Consoli S, Scorrano G, Russo M, di Pietro M, Onofrj M, Sensi SL, and Anzellotti F

Abstract

Anti-N-methyl-D-aspartate receptor (NMDAr) antibody encephalitis is an autoimmune disorder characterized by reduced synaptic activity of the NMDAr due to circulating antibodies that target the NR1 subunit. Few cases of anti-NMDAR encephalitis during pregnancy have been described. The permeation of anti-NR1 antibodies through the placenta can be instrumental in the development of complications in newborns. We describe a case of a young woman suffering from anti-NMDAR encephalitis during the first trimester of pregnancy and focus on diagnostic and therapeutic management., Competing Interests: The authors declare no conflict of interest., (© 2022 The Author(s).)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results